LynparzaTM

Active ingredient
Olaparib
Pharma Company
AstraZeneca GmbH
Total Number of Doctors1
51 doctors
Total Number of Patients2
300 patients
Total minimum fees planned3
336,000.00 €

Observational Studies including LynparzaTM

Drug No. of doctors1 No. of patients2 Payment per patient3
LynparzaTM 51 300 1,120.00 € Baseline: 350€, max. 24 Follow-ups à 30€ (720€), Abschluss 50€

Background

Independent journalism needs independent funding

Others can write stories. We want to reveal. We are the first investigative newsroom in Germany, which is independent, ad-free, and non-profit.

For us, the core of journalism means uncovering injustice and shortcomings in society. That’s why we investigate corruption in the health system, politicians abusing their power, and an elite that believes that rules are for the others.

To do our job, we need people, who support us. We ask you, too, to become a member and enable the work of 16 investigative journalists at CORRECTIV.

We are convinced that without independent and critical media, democracy fought for and won by our ancestors, cannot survive for long.